Santiago PA, Gutiérrez SJ

Language: Spanish
References: 10
Page: 995-1001
PDF size: 472.28 Kb.

ABSTRACT

Insulinoma is a rare pancreatic islet cell tumor characterized by proliferation of beta cells. They are pancreatic neuroendocrine tumors, generally benign and small in size, characterized by insulin hypersecretion syndrome with the development of hypoglycemia. Most of these tumors are sporadic, only about 15-30% are hereditary; it is associated with diseases such as multiple endocrine neoplasia type 1, or Von Hippel-Lindau syndrome. The incidence of this tumor is 3-10 cases per million inhabitants. The average age of onset is between 40-50 years of age and it is more frequent in women. Early recognition and proper diagnosis of this rare pancreatic tumor are important aspects, as it is potentially curable with timely surgical treatment.

REFERENCES

1. Chirinos-Revilla JL, Fernández-Sivincha JG. Insulinoma descubierto en paciente con aparente trastorno mental: reporte de un caso. Rev Gastroenterol Perú [internet]. 2018 [citado 12 jul. 2020];38(1):[aprox. 2 p.]. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1022-512920180001000131.

2. Benalcázar-Villacreses D, González-Era Y, Rodríguez-Álvarez M, Ojeda-Delgado L. Manejo anestésico del insulinoma. Presentación de un caso. Rev Finlay [internet]. 2017 [citado 12 jun. 2022];7(1):[aprox. 4 p.]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/5162.

3. González Quezada A, Romero Garza HH, Reina Sepúlveda FJ, Hernández Guedea MA, Pérez Rodríguez E, Muñoz Maldonado GE. Enucleación laparoscópica de insulinoma. Cir Gen [internet]. dic. 2019 [citado 12 jun. 2022];41(4):[aprox. 2 p.]. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-00992019000400291&lng=es3.

4. Licea-Puig M, Pedroso-Rodríguez H, Raspall-Hidalgo R, Duarte-Vilariño A. Insulinoma maligno: presentación de un caso. Rev Cubana Medicina [internet]. 2020 [citado 12 jun. 2022];18(4):[aprox. 6 p.]. Disponible en: http://revmedicina.sld.cu/index.php/med/article/view/14254.

5. Cerrada Enciso L, Cerrada Enciso B, Cerrada Enciso A, Santamaría Briz D. Insulinoma. A propósito de un caso. Rev Sanitaria Investig [internet]. 2022 [citado 12 jun. 2022];3(1):[aprox. 2 p.]. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=82984305.

6. Licea-Videaux M, Palacios-Morejon I, Zamora-Santana O, Chacón-Melcón R. Paciente positiva a la COVID-19 operada de un insulinoma. Rev Cubana Medicina Militar [internet]. 2021 [citado 12 jun. 2022];51(1):[aprox. 9 p.]. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/15086.

7. Câmara-de-Souza AB, Toyoshima MTK, Giannella ML, Freire DS, Camacho CP, Lourenço DM, et al. Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors. Pancreatol [internet]. 2018 [citado 11 jun. 2022];18(3):[aprox. 5 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29452754/7.

8. Kang I, Kyoung Hwang H, Jung Lee W, Moo Kang CH. First experience of pancreaticoduodenectomy using Revo-i in a patient with insulinom. Ann Hepatob Pancreat Surg [internet]. 2020 [citado 11 jun. 2022];24:[aprox. 4 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32181438/8.

9. Peltola E, Hannula P, Huhtala H, Metso S, Sand J, Laukkarinen J, et al. Long-term morbidity and mortality in patients diagnosed with an insulinoma. Eur J Endocrinol [internet]. 2021 [citado 11 jul. 2022];185(4):[aprox. 9 p.]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34374651/9.

10. Montañez C, Gómez-Pérez R. Insulinoma maligno: presentación de un caso. Rev Venezolana Endocrinol Metabol [internet]. 2019 [citado 11 jun. 2022];17(3):[aprox. 6 p.]. Disponible en: https://www.redalyc.org/journal/3755/375563338004/html/